Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in

Apyx Medical Corp
NASDAQ:APYX

Watchlist Manager
Apyx Medical Corp Logo
Apyx Medical Corp
NASDAQ:APYX
Watchlist
Price: 4.4 USD 9.45% Market Closed
Market Cap: $180.4m
Write Note Create Alert Ask AI
Financials Section:
Income Statement Balance Sheet Cash Flow Statement
|
Revenue Breakdown

Balance Sheet

Assets
+
3Y
+4%
5Y
-24%
10Y
+73%
Liabilities
+
3Y
+287%
5Y
+360%
10Y
+506%
Equity
+
3Y
-86%
5Y
-91%
10Y
-76%

Balance Sheet Decomposition
Apyx Medical Corp

Balance Sheet
Apyx Medical Corp

Rotate your device to view
Balance Sheet
Currency: USD
Dec-2001 Dec-2002 Dec-2003 Dec-2004 Dec-2005 Dec-2006 Dec-2007 Dec-2008 Dec-2009 Dec-2010 Dec-2011 Dec-2012 Dec-2013 Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023 Dec-2024
Assets
Cash & Cash Equivalents
1
0
0
2
1
3
4
3
2
4
5
4
8
6
12
14
10
17
59
42
31
10
44
32
Cash Equivalents
1
0
0
2
1
3
4
3
2
4
5
4
8
6
12
14
10
17
59
42
31
10
44
32
Short-Term Investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
62
0
0
0
0
0
0
Total Receivables
1
1
2
2
2
3
3
3
3
2
2
3
2
2
3
5
5
5
9
17
21
18
14
16
Accounts Receivables
1
1
2
2
2
3
3
3
3
2
2
3
2
2
3
5
5
4
8
8
13
11
14
16
Other Receivables
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
9
8
8
0
0
Inventory
2
2
2
2
3
4
5
5
7
8
8
8
8
6
6
6
7
3
5
4
7
12
10
8
Other Current Assets
1
1
1
1
1
1
1
1
2
1
1
2
2
2
1
1
1
3
4
3
2
3
3
2
Total Current Assets
5
5
5
7
7
10
12
12
13
15
16
16
20
15
22
27
23
90
77
66
61
43
70
56
PP&E Net
2
2
2
2
3
3
3
7
9
7
7
7
7
7
7
6
6
6
8
7
7
8
7
7
PP&E Gross
2
2
2
2
3
3
3
7
9
7
7
0
7
7
0
0
6
6
8
7
7
8
7
7
Accumulated Depreciation
1
1
1
2
2
2
3
4
4
4
5
0
6
6
0
0
7
6
4
5
5
5
4
4
Intangible Assets
1
1
2
2
2
3
4
5
5
3
2
2
2
2
2
2
2
0
0
0
0
0
0
0
Goodwill
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Long-Term Investments
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Long-Term Assets
0
0
0
0
0
0
0
2
1
2
2
3
4
1
1
0
0
0
0
1
1
1
2
2
Other Assets
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Assets
9
N/A
9
-1%
9
+10%
11
+19%
12
+5%
17
+42%
19
+14%
27
+40%
27
+3%
28
+1%
28
+2%
28
0%
33
+18%
25
-25%
31
+27%
35
+12%
31
-12%
96
+210%
85
-12%
74
-13%
69
-7%
52
-25%
79
+53%
65
-18%
Liabilities
Accounts Payable
0
1
1
1
1
1
1
1
1
1
1
1
1
2
1
2
2
1
2
2
3
3
3
3
Accrued Liabilities
1
0
0
1
0
1
1
1
1
1
1
1
1
2
3
3
4
6
8
6
9
6
10
7
Short-Term Debt
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Current Portion of Long-Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Current Liabilities
0
0
0
0
0
0
0
0
0
0
1
0
1
0
0
0
0
1
1
2
2
3
0
1
Total Current Liabilities
1
2
1
1
2
2
2
2
2
2
2
2
3
4
4
5
6
9
12
9
13
12
13
11
Long-Term Debt
0
0
0
0
0
0
0
4
4
4
3
3
3
3
3
3
3
0
0
0
0
0
33
34
Deferred Income Tax
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
0
0
0
0
0
0
0
0
Minority Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Other Liabilities
0
0
0
0
0
0
0
0
0
1
0
0
6
13
0
0
0
0
1
1
1
2
6
6
Total Liabilities
2
N/A
2
+27%
2
-3%
2
-2%
2
+3%
3
+34%
2
-8%
6
+163%
6
+1%
6
-6%
6
+2%
5
-14%
12
+124%
20
+70%
8
-60%
9
+11%
9
+1%
9
-2%
13
+54%
10
-23%
15
+45%
14
-6%
53
+270%
51
-4%
Equity
Common Stock
0
0
0
0
0
0
0
0
0
0
0
0
2
3
0
0
0
0
0
0
0
0
0
0
Retained Earnings
13
13
13
11
11
8
6
2
2
3
3
3
10
28
19
23
29
34
15
3
13
36
54
78
Additional Paid In Capital
20
20
20
20
21
22
22
23
23
25
25
26
29
29
43
50
51
53
57
61
66
73
81
92
Other Equity
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Equity
7
N/A
6
-7%
7
+15%
9
+24%
10
+6%
14
+43%
17
+18%
20
+22%
21
+3%
22
+4%
22
+2%
23
+4%
21
-7%
5
-78%
23
+399%
26
+12%
22
-16%
87
+296%
71
-18%
64
-11%
54
-16%
38
-30%
27
-29%
14
-47%
Total Liabilities & Equity
9
N/A
9
-1%
9
+10%
11
+19%
12
+5%
17
+42%
19
+14%
27
+40%
27
+3%
28
+1%
28
+2%
28
0%
33
+18%
25
-25%
31
+27%
35
+12%
31
-12%
96
+210%
85
-12%
74
-13%
69
-7%
52
-25%
79
+53%
65
-18%
Shares Outstanding
Common Shares Outstanding
13
13
13
14
14
15
15
17
17
18
18
18
18
18
27
31
33
34
34
34
34
35
35
38
Preferred Shares Outstanding
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

See Also

Summary
APYX intrinsic value, competitors valuation, and company profile.
DCF Valuation
APYX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
APYX stock valuation using valuation multiples.
Wall Street Estimates
APYX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
APYX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Follow us
Join more than 314,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.